Merck KGaA announced an agreement to acquire Bio-Techne for about $11.3 billion, extending its footprint across the life-science workflow from discovery through advanced therapeutics and manufacturing. The deal adds Bio-Techne’s multiomics, analytics, and integrated workflow solutions, positioning the combined entity as a broader platform provider. Merck KGaA also framed the acquisition as a way to strengthen cell-therapy tool access, including Bio-Techne’s involvement with Wilson Wolf cell culture devices. The transaction adds another high-value instrument and consumables supplier to Merck’s existing portfolio after a sequence of large acquisitions. For the ecosystem, the main impact is consolidation in the research tools layer, where multiomics data, assays, and process-adjacent consumables increasingly determine how efficiently therapies move from bench to clinic.